This article aims to explore the effects and possible mechanism of miR-543 on small-cell lung carcinoma (SCLC) cells. The respective levels of miR-543 in lung carcinoma tissues, para-cancerous tissues, human normal lung cells MRC-9, and SCLC cells were detected by RT-qPCR. The proliferation, apoptosis, and migration of SCLC cells were detected after the miR-543 level in SCLC cells was altered by miRNA mimics and inhibitors. The levels of apoptosis-related proteins and potential downstream targeted proteins of miR-543 were detected by western blots. The study revealed that KNTC1 was highly expressed in lung carcinoma tissues and SCLC cells (P < 0.01). It also showed that knockdown of miR-543 can inhibit the proliferation and migration of SCLC cells, induce apoptosis, and increase the level of apoptosis-related proteins. These changes were reversed by the addition of mimics that increased miR-543 levels. The level of miR-543 was positively correlated with the protein expression level of downstream MUC1, β-catenin, and CDC42 in SCLC cells, suggesting that miR-543 may play a role through them. Thus this study concludes that MiR-543 can affect the function of SCLC cells, which may play a crucial role in the presence and development of SCLC.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1615/CritRevEukaryotGeneExpr.2021037227 | DOI Listing |
J Clin Med
January 2025
Department of Clinical Therapeutics, Alexandra General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Paraneoplastic cerebellar degeneration (PCD) is an inflammatory autoimmune process caused by onconeural antibodies directed against cerebellar Purkinje cells. In most cases, prognosis is poor as disease progression leads to pancerebellar dysfunction and permanent neurological damage. Through this case report, we aim to highlight the clinical presentation, diagnostic process, and therapeutic implications associated with PCD secondary to SCLC.
View Article and Find Full Text PDFACS Nano
January 2025
Key Laboratory of Bioinorganic and Synthetic Chemistry of Ministry of Education, LIFM, School of Chemistry, IGCME, Sun Yat-Sen University, Guangzhou 510275, China.
Perovskite solar cells (PSCs) have emerged as low-cost photovoltaic representatives. Constructing three-dimensional (3D)/two-dimensional (2D) perovskite heterostructures has been shown to effectively enhance the efficiency and stability of PSCs. However, further enhancement of device performance is still largely limited by inferior conductivity of the 2D perovskite capping layer and its mismatched energy level with the 3D perovskite layer.
View Article and Find Full Text PDFJ Med Chem
January 2025
Department of Respiratory and Critical Care Medicine, Molecularly Targeted Research and Development Laboratory, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China.
To overcome the compensatory effect between Topo I and II, one of the reasons accounting for the resistance of SCLC patients, we are pioneering the use of 3-arylisoquinolines to develop dual inhibitors of Topo I/II for the management of SCLC. A total of 46 new compounds were synthesized. Compounds (IC = 1.
View Article and Find Full Text PDFCrit Rev Oncol Hematol
January 2025
Institute of Biomedicine of Seville (IBiS), HUVR, CSIC, University of Seville, Seville 41013, Spain; Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid 28029, Spain. Electronic address:
Small cell lung cancer (SCLC) remains a challenge in oncology due to its aggressive behavior and dismal prognosis. Despite advances in treatments, novel strategies are urgently needed. Enter liquid biopsy-a game-changer in SCLC management.
View Article and Find Full Text PDFJ Thorac Dis
December 2024
Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Background: Small cell lung cancer (SCLC) accounts for 15% of all lung cancers and presents early metastasis and poor prognosis. Chemotherapy with cisplatin (CDDP) remains one of the standards of care in first-line treatment. However, the emergence of acquired resistance to CDDP causes disease progression and cancer recurrence.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!